by Deliberato Law Center | Jul 18, 2022 | Elder Law, Estate Planning Education, Probate, Uncategorized
A trust is like an Easter basket in that it only really exists when full. Until you fill that wicker frame with chocolate eggs and other goodies, it’s nothing more than, well, a frame. Likewise, until you fund a trust with assets, it’s nothing more than legal...
by Deliberato Law Center | Jun 30, 2022 | Elder Law, Estate Planning Education, Uncategorized
A dementia diagnosis is a traumatic time for any family. Dementia happens slowly and progressively over time. In the early stages, some symptoms are often thought of as just signs of aging. Beginning signs can be as simple as losing car keys, forgetting where the car...
by Deliberato Law Center | Jun 23, 2022 | Elder Law, Estate Planning Education, Uncategorized
Everyone agrees that doing the right thing is, well, the right thing to do, but many stall out trying to figure out what this means. Should you make monthly donations to a cause close to your heart? Support a political party that shares your values? Volunteer your...
by Deliberato Law Center | May 23, 2022 | Elder Law, Estate Planning Education, Probate, Uncategorized
What do Jimi Hendrix, Bob Marley, Pablo Picasso, Steve McNair, Aretha Franklin, and Abraham Lincoln have in common? No, it’s not that they’re all dead (though, yes, they are). It’s not even that they’re all famous (however true, that would be too easy). It’s that they...
by Deliberato Law Center | Feb 18, 2022 | Elder Law, Estate Planning Education, Uncategorized
A person turning 65 today has a nearly 70% chance of needing some form of long term care during their golden years. Women, on average, will require 3.7 years of care while men, who statistically live shorter lives, will require 2.2 years. In 2020, the cost of long...
by Deliberato Law Center | Jan 27, 2022 | Elder Law, Estate Planning Education, Medicaid, Uncategorized
The Food and Drug Administration (FDA) has approved a drug purported to slow the progress of Alzheimer’s disease. However, the decision is not without controversy. A recent article by AARP explores this subject in some detail. Here is a synopsis. The drug, Aducanumab...
Recent Comments